Equities Analysts Set Expectations for PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of ProQR Therapeutics in a research note issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biopharmaceutical company will post earnings per share of ($0.39) for the year. Cantor Fitzgerald has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

PRQR has been the subject of several other research reports. Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They set an "outperform" rating and a $15.00 price target for the company. Chardan Capital restated a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, March 14th. HC Wainwright increased their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, March 14th. Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research report on Monday, March 10th. Finally, Evercore ISI initiated coverage on ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.75.

ProQR Therapeutics Price Performance

PRQR stock traded down $0.19 during trading on Thursday, reaching $1.80. The company had a trading volume of 884,050 shares, compared to its average volume of 612,228. The company has a market cap of $189.38 million, a P/E ratio of -5.63 and a beta of 0.35. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The business has a 50 day moving average of $1.56 and a 200 day moving average of $2.47.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. OneDigital Investment Advisors LLC boosted its holdings in ProQR Therapeutics by 45.5% during the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 12,500 shares during the period. Vontobel Holding Ltd. bought a new position in shares of ProQR Therapeutics during the 1st quarter worth approximately $48,000. Alpine Global Management LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $39,000. Woodline Partners LP acquired a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $9,426,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth $107,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).